The 2-Minute Rule for Atabecestat
All enrolled individuals who been given not less than a single dose of zosuquidar or placebo through induction were monitored to the prevalence of adverse occasions (439 sufferers, 219 on zosuquidar and 210 on placebo). The most typical adverse situations were linked to the period of prolonged and important myelosuppression as is predicted with ind